Curran Terrie — SEC insider filings

SEC reporting owner CIK 1690298. 34 insider filings on record with FilingPulse; latest filed 2026-08-28.

Transaction summary — filings shown

Covers all 34 filings on record, filed 2020-09-17 to 2026-08-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Phathom Pharmaceuticals, Inc. (PHAT)President and Chief Executive, Director182 legs · 33,419 sh · $252,8618 legs · 90,104 sh · $1,249,49015
Myovant Sciences Ltd. (MYOV)Director6—3 legs · 53,358 sh · $1,337,87717
Arcutis Biotherapeutics, Inc. (ARQT)Director10—4 legs · 47,959 sh · $1,078,27418

Insider filings — Curran Terrie

FiledFormIssuerReported transactionsSource
2026-08-284Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 11,148 @ $7.51 · Sale (S): 11,148 @ $25.03 · Option exercise (M): 27,052 @ $8.63 · Sale (S): 27,052 @ $25.03 · Option exercise (M): 11,148 (derivative) @ $0 · Option exercise (M): 27,052 (derivative) @ $0EDGAR
2026-08-244Arcutis Biotherapeutics, Inc. (ARQT)Option exercise (M): 1,072 @ $7.51 · Sale (S): 1,072 @ $26.04 · Option exercise (M): 1,072 (derivative) @ $0EDGAR
2026-06-094Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0EDGAR
2025-06-164Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 7,609 @ $0 · Grant/award (A): 20,568 (derivative) @ $0EDGAR
2025-03-034Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 342,500 (derivative) @ $0EDGAR
2025-01-234Phathom Pharmaceuticals, Inc. (PHAT)Sale (S): 19,109 @ $6.59EDGAR
2024-11-134Arcutis Biotherapeutics, Inc. (ARQT)Sale (S): 8,687 @ $10.85EDGAR
2024-07-174Phathom Pharmaceuticals, Inc. (PHAT)Sale (S): 33,848 @ $11.72EDGAR
2024-06-184Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 10,139 @ $0 · Grant/award (A): 27,052 (derivative) @ $0EDGAR
2024-03-264Phathom Pharmaceuticals, Inc. (PHAT)Sale (S): 16,851 @ $9.11EDGAR
2024-01-224Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 475,000 (derivative) @ $0EDGAR
2023-11-034Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 37,500 @ $0EDGAR
2023-07-174Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 200,000 · Disposition to issuer (D): 175,000 (derivative) · Disposition to issuer (D): 225,000 (derivative)EDGAR
2023-06-024Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,375 @ $0 · Grant/award (A): 12,220 (derivative) @ $0EDGAR
2023-04-074Phathom Pharmaceuticals, Inc. (PHAT)Purchase (P): 12,919 @ $7.82EDGAR
2023-03-104Myovant Sciences Ltd. (MYOV)Disposition to issuer (D): 3,673 · Disposition to issuer (D): 33,846 (derivative) · Disposition to issuer (D): 11,154 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 5,250 (derivative) · +2 moreEDGAR
2023-03-034Phathom Pharmaceuticals, Inc. (PHAT)Sale (S): 1,436 @ $8.54EDGAR
2023-01-204Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 97,500 @ $0 · Sale (S): 5,821 @ $8.20 · Grant/award (A): 162,500 (derivative) @ $0EDGAR
2022-11-234Phathom Pharmaceuticals, Inc. (PHAT)Sale (S): 1,526 @ $9.60EDGAR
2022-10-284Myovant Sciences Ltd. (MYOV)Grant/award (A): 9,859 @ $0EDGAR
2022-09-024Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 7,500 @ $0EDGAR
2022-06-034Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 4,312 @ $0 · Grant/award (A): 11,796 (derivative) @ $0EDGAR
2022-05-204Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 12,000 @ $0EDGAR
2022-05-164Phathom Pharmaceuticals, Inc. (PHAT)Purchase (P): 20,500 @ $7.41EDGAR
2022-03-114/APhathom Pharmaceuticals, Inc. (PHAT)Holdings only — no transactions reportedEDGAR
2022-01-214Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 41,250 @ $0 · Grant/award (A): 206,250 (derivative) @ $0EDGAR
2021-11-094Myovant Sciences Ltd. (MYOV)Grant/award (A): 21,096 (derivative) @ $0EDGAR
2021-09-134Myovant Sciences Ltd. (MYOV)Option exercise (M): 4,850 @ $7.65 · Sale (S): 4,850 @ $25.58 · Option exercise (M): 4,850 (derivative) @ $0EDGAR
2021-09-034Myovant Sciences Ltd. (MYOV)Option exercise (M): 11,373 @ $7.65 · Sale (S): 11,373 @ $25 · Option exercise (M): 37,135 @ $7.65 · Sale (S): 37,135 @ $25.03 · Option exercise (M): 11,373 (derivative) @ $0 · Option exercise (M): 37,135 (derivative) @ $0EDGAR
2021-06-114Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 13,391 (derivative) @ $0EDGAR
2021-03-234Phathom Pharmaceuticals, Inc. (PHAT)Option exercise (M): 11,513 @ $6.95 · Sale (S): 10,373 @ $43.24 · Sale (S): 1,140 @ $44.08 · Option exercise (M): 11,513 (derivative) @ $0EDGAR
2021-01-294Phathom Pharmaceuticals, Inc. (PHAT)Grant/award (A): 225,000 (derivative) @ $0EDGAR
2020-11-044Arcutis Biotherapeutics, Inc. (ARQT)Grant/award (A): 37,500 (derivative) @ $0EDGAR
2020-09-174Myovant Sciences Ltd. (MYOV)Grant/award (A): 21,603 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1690298 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs